Flexbumin 200 g/l
Ask a doctor about a prescription for Flexbumin 200 g/l
How to use Flexbumin 200 g/l
Package Leaflet: Information for the User
Flexbumin 200 g/l, Solution for Infusion
Human Albumin
Read the package leaflet carefully before using the medicine, as it contains important information for the patient.
- Keep this package leaflet, you may need to read it again.
- If you have any further questions, ask your doctor, pharmacist, or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
- If you experience any side effects, including any not listed in this leaflet, please tell your doctor, pharmacist, or nurse. See section 4.
Contents of the Package Leaflet
- 1. What is Flexbumin 200 g/l and what is it used for
- 2. Important information before using Flexbumin 200 g/l
- 3. How to use Flexbumin 200 g/l
- 4. Possible side effects
- 5. How to store Flexbumin 200 g/l
- 6. Contents of the pack and other information
1. What is Flexbumin 200 g/l and what is it used for
Flexbumin 200 g/l is a solution of plasma protein and belongs to the pharmacotherapeutic group of plasma substitutes and plasma protein fractions. Plasma is the liquid part of the blood in which blood cells are suspended.
It is used to supplement and maintain blood volume in cases where blood volume is too low.
2. Important information before using Flexbumin 200 g/l
When not to use Flexbumin 200 g/l:
- If the patient is allergic to human albumin or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
Before starting treatment with Flexbumin 200 g/l, discuss it with your doctor, pharmacist, or nurse.
- If during treatment you experience headache, difficulty breathing, or a feeling of weakness, you should immediately inform your doctor or nurse. This may be an allergic reaction.
- If the patient has any of the following diseases:
- uncompensated heart failure
- hypertension
- esophageal varices (enlarged veins in the esophagus)
- pulmonary edema (fluid in the lungs)
- tendency to spontaneous bleeding
- severe anemia (lack of red blood cells)
- reduced urine production, inform your doctor so that they can take appropriate precautions.
In the case of receiving medicinal products from human blood or plasma, certain measures are taken to prevent the transmission of infections. These include careful selection of donors to exclude individuals who may be at risk of transmitting infections, and testing of individual donations and plasma pools for signs of virus/infection. Manufacturers of such products also include virus inactivation or removal steps in the blood and plasma processing process. Despite this, it cannot be completely ruled out that infectious agents may be transmitted when administering medicinal products obtained from human blood or plasma. This also applies to unknown and newly discovered viruses and other pathogens.
There have been no reports of virus transmission with albumin preparations produced using an approved process, in accordance with the specifications given in the European Pharmacopoeia.
It is recommended that each time Flexbumin 200 g/l is administered, the name and batch number of the preparation should be recorded in order to maintain information on the batches of the medicine used.
Flexbumin 200 g/l and other medicines
Tell your doctor or pharmacist about all the medicines you are taking now or have recently taken, as well as any medicines you plan to take.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, ask your doctor or pharmacist for advice before using this medicine. Your doctor will decide whether you can use Flexbumin 200 g/l during pregnancy or breastfeeding.
The effect of Flexbumin 200 g/l on fertility has not been studied.
Children and adolescents
In clinical trials sponsored by the company, the safety and efficacy of human albumin solution in children and adolescents have not been established. Due to the limited data available on the use of Flexbumin 200 g/l in children, this medicine should only be used when the benefits clearly outweigh the potential risks.
Driving and using machines
No effect on the ability to drive and use machines has been observed.
Flexbumin 200 g/l contains sodium
50 ml bag:
The medicine contains 149.5-184 mg of sodium (the main component of common salt) in each bag. This corresponds to 7.5-9.2% of the maximum recommended daily intake of sodium in the diet for adults.
100 ml bag:
The medicine contains 299-368 mg of sodium (the main component of common salt) in each bag. This corresponds to 15-18.4% of the maximum recommended daily intake of sodium in the diet for adults.
3. How to use Flexbumin 200 g/l
Flexbumin 200 g/l is a medicine intended for use in a hospital setting. Therefore, it will be administered in a hospital by the appropriate medical staff. The treating doctor will determine the dose, frequency of administration, and duration of treatment, depending on the individual patient's condition.
Using a higher dose of Flexbumin 200 g/l than recommended
Flexbumin 200 g/l is administered only under the strict supervision of a doctor. Therefore, overdose is very unlikely. However, in the case of too high a dose or infusion rate, excessive increase in blood volume (hypervolemia) may occur. This can lead to overloading of the heart and circulatory system (circulatory overload). The first symptoms of such an overdose include:
- headache,
- difficulty breathing (dyspnea),
- enlargement of neck veins (neck vein distension). If such symptoms occur, you should immediately inform your doctor, pharmacist, or nurse.
Your doctor, pharmacist, or nurse may also notice symptoms such as:
- increased blood pressure (hypertension),
- increased central venous pressure,
- presence of fluid in the lungs (pulmonary edema). In all such cases, the doctor, pharmacist, or nurse must immediately stop the infusion, and the patient's hemodynamic parameters must be closely monitored.
Using Flexbumin 200 g/l in children and adolescents
The doctor will decide whether children and adolescents can receive Flexbumin 200 g/l.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
| Very common | occurs in more than 1 in 10 treated patients |
| Common | occurs in less than 1 in 10 but more than 1 in 100 treated patients |
| Uncommon | occurs in less than 1 in 100 but more than 1 in 1000 treated patients |
| Rare | occurs in less than 1 in 1000 but more than 1 in 10,000 treated patients |
| Very rare | occurs in less than 1 in 10,000 treated patients, including single cases |
| Very common | Common | Uncommon | Rare | Very rare | |
| Immune system disorders | anaphylactic shock | ||||
| Gastrointestinal disorders | nausea (feeling sick) | ||||
| Skin and subcutaneous tissue disorders | sudden redness, skin rash | ||||
| General disorders and administration site conditions | fever |
- Rarely occurring side effects usually disappear quickly after reducing the infusion rate or stopping the infusion.
- In the event of shock (severe allergic reaction), the infusion should be stopped immediately and appropriate treatment started.
- If any of the side effects get worse, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Other side effects observed after the introduction of human albumin to the market include:
hypersensitivity/allergic reactions, headache, rapid heartbeat, low blood pressure, apnea or discomfort during breathing, vomiting, altered taste, urticaria, itching, chills, myocardial infarction, irregular heartbeat, fluid accumulation in the lung.
Additional side effects in children and adolescents
Data on the safety of use in children and adolescents are limited. No additional side effects are known in children and adolescents.
Reporting side effects
If you experience any side effects, including any not listed in this leaflet, please tell your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Aleje Jerozolimskie 181 C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of this medicine.
5. How to store Flexbumin 200 g/l
Keep the medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the bag and carton. The expiry date refers to the last day of the month.
Do not store above 25°C.
Do not freeze.
Store the bag in the outer carton to protect from light.
The contents should be used immediately after opening the package.
Do not use this medicine if the solution is cloudy or contains sediment.
6. Contents of the pack and other information
What Flexbumin 200 g/l contains
- The active substance is human albumin. 1 liter of solution contains 200 g of total protein, of which at least 95% is human albumin.
- The other ingredients are: sodium chloride, sodium caprylate, sodium acetyltryptophanate, and water for injections. Total sodium ion content: 130 - 160 mmol/l
What Flexbumin 200 g/l looks like and contents of the pack
Flexbumin 200 g/l is a solution for infusion in a bag.
Pack sizes:
24 x 50 ml (2 cartons of 12 pieces or a carton containing 24 pieces)
12 x 100 ml (2 cartons of 6 pieces or a carton containing 12 pieces)
1 x 50 ml (1 piece)
1 x 100 ml (1 piece)
The solution is clear and slightly viscous, almost colorless, yellow, amber, or green.
Marketing authorization holder and manufacturer
Marketing authorization holder:
Takeda Pharma Sp. z o.o.
ul. Prosta 68
00-838 Warsaw
Manufacturer:
Takeda Manufacturing Austria AG
Industriestrasse 67
1221 Vienna, Austria
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
Austria
Flexbumin 200 g/l - Infusionslösung
Croatia
Flexbumin 200 g/l solution for infusion
Cyprus
Flexbumin 200 G/L
Czech Republic
Flexbumin
Denmark
Flexbumin
Estonia
Flexbumin 200 g/l
Greece
FLEXBUMIN Διάλυμα για έγχυση 200 G/L
Hungary
Flexbumin 200 g/l oldatos infúzió
Iceland
Flexbumin 200 g/l, innrennslislyf, lausn
Ireland
Flexbumin 200 g/l
Italy
FLEXBUMIN
Latvia
Flexbumin 200 g/l šķīdums infūzijām
Liechtenstein
Flexbumin 200 g/l
Lithuania
Flexbumin 200 g/l infuzinis tirpalas
Malta
Flexbumin 200 g/l
Netherlands
Flexbumin 200 g/l, oplossing voor infusie
Norway
Flexbumin 200 g/l
Poland
Flexbumin 200 g/l
Portugal
FLEXBUMIN
Slovakia
Flexbumin 200 g/l
Slovenia
Flexbumin 200 g/l raztopina za infundiranje
Spain
Flexbumin 200 g/l solución para perfusión
United Kingdom
Flexbumin 200 g/l
Date of last revision of the leaflet:12/2021
Information intended for healthcare professionals only:
Before and during administration of Flexbumin 200 g/l
- Albumin solutions should not be diluted with water for injections, as this may cause hemolysis in patients receiving the medicine.
- In the case of administration of large volumes, the product should be warmed to room temperature or body temperature before use.
- For safety reasons, the name and batch number of Flexbumin 200 g/l administered to the patient should be recorded.
- If the dose and infusion rate are not adjusted to the patient's circulatory status, overhydration may occur. If the first clinical signs of circulatory overload (headache, dyspnea, neck vein distension) or increased blood pressure, increased venous pressure, or pulmonary edema occur, the infusion should be stopped immediately.
układu krążenia (ból głowy, duszność, przepełnienie żył szyjnych) lub wzrostu ciśnienia krwi,
zwiększenia ciśnienia żylnego lub obrzęku płuc, należy natychmiast przerwać infuzję.
Preparation for administration
Flexbumin 200 g/l can be administered directly intravenously or after dilution in an isotonic solution (e.g., 5% glucose or 0.9% sodium chloride).
Administration of Flexbumin 200 g/l
- Do not use the bag if the tip protector is damaged, removed, or missing.
- Use only if the bag's welds are intact. Discard if a leak is detected.
- Do not use cloudy or sediment-containing solutions. This may indicate that the protein is unstable or that the solution has been contaminated. Infusion is performed intravenously using a single-use, sterile, and apyrogenic infusion set. Before introducing the infusion set into the bag port, the port should be disinfected using an appropriate antiseptic agent. After connecting the infusion set to the bag, the administration of the solution should be started immediately.
- The infusion rate should be adjusted to the individual situation and indications. During plasma exchange, the infusion rate should be adjusted to the rate of removal.
Shelf life
The contents should be used immediately after opening the package. Any unused product or waste material should be disposed of in accordance with local requirements.
Incompatibilities
This medicinal product should not be mixed with other medicines (except for isotonic solutions, such as 5% glucose or 0.9% sodium chloride), whole blood, and red blood cell concentrates. Human albumin should also not be mixed with protein hydrolysates (e.g., parenteral nutrition) or solutions containing alcohol, as such combinations may cause protein precipitation.
- Country of registration
- Active substance
- Prescription requiredYes
- Manufacturer
- ImporterTakeda Manufacturing Austria AG
- This information is for reference only and does not constitute medical advice. Always consult a licensed doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to Flexbumin 200 g/lDosage form: Solution, 200 g/lActive substance: albuminManufacturer: Biotest Pharma GmbHPrescription not requiredDosage form: Solution, 200 g/lActive substance: albuminPrescription requiredDosage form: Solution, 50 g/lActive substance: albuminPrescription required
Alternatives to Flexbumin 200 g/l in other countries
The best alternatives with the same active ingredient and therapeutic effect.
Alternative to Flexbumin 200 g/l in Spain
Alternative to Flexbumin 200 g/l in Ukraine
Online doctors for Flexbumin 200 g/l
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for Flexbumin 200 g/l – subject to medical assessment and local rules.
Get updates and exclusive offers
Be the first to know about new services, marketplace updates, and subscriber-only promos.
